BC Cho, E Felip, H Hayashi, M Thomas,
S Lu… - Future …, 2022 - Taylor & Francis
Third-generation EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib, have
demonstrated efficacy in patients with EGFR-mutant non-small-cell lung cancer; however …